Thrombocytopenia or thrombocytosis? Nancy Rosenthal, MD.

Slides:



Advertisements
Similar presentations
Paroxysmal Nocturnal Hemoglobinuria Paul M. Johnson Department of Internal Medicine University of North Carolina Hospitals April 6, 2010.
Advertisements

Spliceosome mutations in myeloid neoplasms
JAK2V617F mutation for the early diagnosis of Ph − myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis by Francesco Dentali,
NEOPLASTIC DISORDERS OF THE BONE MARROW
Myelodysplastic syndromes Achievements in understanding and treatment prof. dr hab. med. Krzysztof Lewandowski.
Myelodysplastic Syndrome
MPD. Myeloproliferative neoplasms (MPN) constitute one of five categories of myeloid malignancies, according to the World Health Organization (WHO) classification.
The genetic basis of myelodysplasia and its clinical relevance
Increased peripheral platelet destruction and caspase-3– independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients by.
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.
Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,
The myelodysplastic syndromes (MDS) Aquired Clonal disease of BM. comprise a heterogeneous group of malignant stem cell disorders characterized by : 1.
MLAB HEMATOLOGY KERI BROPHY-MARTINEZ Myelodysplastic Syndromes.
CB-1 MDS Classification and Prognosis John M. Bennett, MD University of Rochester Medical Center Hematomorphologist Chair, MDS Foundation.
Myelodysplastic Syndromes Tefferi A, Vardiman JW. New Engl J Med 2009:361(19):
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms by Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser,
Good morning… My presentation is about Calreticulin and PMF
MLAB Hematology Keri Brophy-Martinez
Authors: Preetam Nath Prof Madhukar Rai Serum Lactate Dehydrgenase as a differentiating tool between Megaloblastic & Non-Megaloblastic Macrocytic anemia.
October 2014 Myeloproliferative Neoplasms Angela Fleischman Division of hematology/Oncology.
Case 255 Elizabeth Courville, MD Robert Hasserjian, MD Massachusetts General Hospital Society for Hematopathology/European Association for Haematopathology.
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts by Luca Malcovati, Mohsen Karimi, Elli Papaemmanuil, Ilaria.
Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.
1 Oliva EN et al Proc ASH 2015;Abstract 91.
Myelodysplastic Syndromes
MLAB Hematology Keri Brophy-Martinez
Algorithm for the classification of adult-onset primary myelodysplastic syndromes (MDS). This classification system is based on the 2008 criteria of the.
HS 4160 Critical Scientific Analysis
Beyond Supportive Care for Lower-Risk Myelodysplastic Syndrome
Chronic Myeloproliferative Neoplasms (MPN) Ph-negative
Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study by Lori-Ann Linkins,
Biology of MDS/MPN overlap syndromes (except CMML)
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Chronic Myelomonocytic Leukemia: Focus on Clinical Practice
Validation of the Nordic Scoring System for Erythropoietic Stimulating Agents in MDS Using IWG 2006 Erythroid Response Criteria by Jennifer Jayakar, Richard.
Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,
V617F “JAKs” up myeloproliferative signal
by Mario Cazzola, Marianna Rossi, and Luca Malcovati
Myelodysplastic Syndromes
Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.
Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,
by Alexander Röth, Andreas Hüttmann, Russell P
by Ernest Beutler Blood Volume 98(9): November 1, 2001
The genetic basis of myelodysplasia and its clinical relevance
by Bartlomiej Przychodzen, Andres Jerez, Kathryn Guinta, Mikkael A
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
by R. Coleman Lindsley, and Benjamin L. Ebert
Erythroid karyorrhexis in myelodysplasia: bone marrow aspirate
How I treat catastrophic thrombotic syndromes
by Valeria Visconte, Heesun J
Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation 
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Dehydrated hereditary stomatocytosis masquerading as MDS
Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes by Abdullah Mahmood Ali, Yumin Huang,
Lyons RM et al. J Clin Oncol 2009;27(11):
Pathogenesis of myeloproliferative neoplasms
by Alex Aleshin, and Peter L. Greenberg
A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.
In the name of god.
A case of lenalidomide-dependent myelodysplastic syndrome
Distribution of podocyte gene mutations in patients with genetic congenital nephrotic syndrome (CNS) and steroid–resistant nephrotic syndrome (SRNS). Distribution.
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
X-linked thrombocytopenia identified by flow cytometric demonstration of defective Wiskott-Aldrich syndrome protein in lymphocytes by Hirokazu Kanegane,
by Elisa Rumi, and Mario Cazzola
A previously healthy 43-year-old man with chronic alcoholism presented to a rural medical center with a 2-week history of confusion, fever, dyspnea, dizziness,
Schematic representations of pulmonary hypertension.
How I treat essential thrombocythemia
How I treat T-cell acute lymphoblastic leukemia in adults
Cold agglutinin disease
Presentation transcript:

Thrombocytopenia or thrombocytosis? Nancy Rosenthal, MD

Case history 65 year old female Outside case referred for a second opinion No CBC data was sent with the case

Refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) New WHO (coming 2016) will likely change this from a provisional to a full entity Classified as an overlap syndrome (MDS/MPN) Must be a de novo diagnosis, not arising from an myelodysplastic syndrome with ring sideroblasts Often has both a JAK2 mutation and SF3B1 mutation

RARS-T MPN –like – Thrombocytosis – Need cytoreduction – Megs are clustered, bulbous, large – JAK2+, rarely CALR/MPL+ MDS- like – Macrocytic anemia – Require transfusions – Ring sideroblasts – Erythroid dyspoiesis – SF3B1+ (80-90%)

Schematic representation of our current understanding of the relationship between the occurrence of a somatic SF3B1 mutation and the formation of ring sideroblasts in patients with RARS. Previous studies found reduced expression of ABCB7 in CD34-positive ce... Cazzola M et al. Blood 2013;121: ©2013 by American Society of Hematology